Replies to post #95643 on Cytodyn Inc (CYDY)

[daemon57]

Saltz - love your posts, thanks for the insights. Really do appreciate on this this fine Sunday morning. GTLU/A.

[Amatuer17]

“On another note, if NP is going to PR the M2M results on Tuesday as he has stated, they will be the cherry picked results because their is no way he can have ALL endpoints collated by Tuesday. Question is, is this wise? “

I had the same concerns -
primary + secondary + other - total the trial has 17 outcomes - RANTES, CCR5 measurement are in other category and very important.

I hope NP does not do another screw up in his hasty moves. He had promised results next week so he could have done that by Thur/Fri - hope he includes all key data elements to impress and grab attention.

[3X Charm]

Dead on Saltz from what I have been personally told about NP’s style. The concern, not so much for COVID, but for HIV and other indications is his lack of experience in manufacturing , sales and distribution of the product. It is one thing to have a great product it is another thing for it to be adopted by the market. Hopefully COVID provides the $ and time for NP to understand the pharma industry.

As an FYI to all: Some folks are posting about never selling a share and keeping it for 10 years. Do yourself a favor and read “The Future is Faster Than You Think.”. The convergence of science, money and computing is allowing hyper speed changes in all industries. Even if leronlimab knocks it out of the park next week, the week after, there could be something discovered that is better. Not giving investment advice...

Continued thanks for all the Posters providing useful info. For the others thanks for the laughs.

Gd Bless America!

[The oNiOnHEAd]

Maybe I'm wrong, but I don't see why it would take so long to perform all required analysis on the data. The data should have been entered into a database at all points of collection. After the number of clinical trials that have already been conducted, many house written analysis routines would already be on hand, and tweaking of existing routines, or writing of routines specific to Covid-19 trial, should have already been finished long before this first Covid-19 study was completed. I suspect many biochemical developers use standard clinical trial software analysis packages:

https://financesonline.com/clinical-trial-management/